Prostate cancer 2022: AI-guided therapy and a new standard in high-risk disease
Click Here to Manage Email Alerts
Several novel treatment regimens for prostate cancer emerged during the past year.
In addition, researchers highlighted the potential role of artificial intelligence to guide treatment decisions, and hypofractionated radiation therapy emerged as a new standard for certain men.
Healio shares the following developments in prostate cancer research and treatment from the past year that may be relevant to your practice.
1. Men with high-risk prostate cancer who received a shorter course of radiation therapy had similar survival and recurrence rates as those who received a longer, standard radiation therapy course. The findings suggest a 5-week hypofractionated radiation therapy regimen should be a new standard for men with high-risk disease eligible for external beam radiation and long-term androgen deprivation therapy. Read more.
2. Prostate cancer clinical trials included significant underrepresentation of Asian, Black and Hispanic men based on incidence of the disease among these groups, results of meta-analysis published in JAMA Oncology showed. Read more.
3. Long-course ADT extended metastasis-free survival compared with short-course ADT when added to radiotherapy after radical prostatectomy, randomized phase 3 results showed. Read more.
4. Enzalutamide (Xtandi; Astellas, Pfizer) monotherapy induced significant treatment response among men on active surveillance for low- or intermediate-risk localized prostate cancer. Read more.
5. The FDA approved darolutamide (Nubeqa, Bayer) tablets in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer. Read more.
6. PSA screening appeared associated with lower prostate cancer-specific mortality among both Black men and non-Hispanic white men. Read more.
7. Preoperative MRI led to significantly fewer postoperative complications among men undergoing prostatectomy. Read more.
8. The addition of ADT to radiotherapy improved survival among men with localized prostate cancer. Read more.
9. The FDA approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis) for treatment of certain men with advanced prostate cancer. Read more.
10. Increases in metastatic prostate cancer incidence may be temporarily associated with changes in clinical policy following U.S. Preventive Services Task Force recommendations. Read more.
11. The addition of darolutamide to ADT and docetaxel prolonged OS among men with metastatic hormone-sensitive prostate cancer. Read more.
12. An AI-derived digital pathology-based biomarker (ArteraAI-Predict ADT) may help guide treatment decisions for men with localized intermediate-risk prostate cancer. Read more.
13. The addition of niraparib (Zejula) to abiraterone acetate (Zytiga, Janssen) and prednisone improved outcomes for certain men with prostate cancer. Read more.
14. The addition of olaparib (Lynparza; AstraZeneca, Merck) to abiraterone acetate (Zytiga, Janssen) significantly extended radiographic PFS at first-line treatment for metastatic castration-resistant prostate cancer. Read more.
Collapse
Healio Coverage
Read more about
Click Here to Manage Email Alerts